PHASE 1/2 STUDY: FRONTLINE BRENTUXIMAB VEDOTIN plus AVD IN PEDIATRIC PTS WITH ADVANCED HODGKIN LYMPHOMA

被引：0
|
作者：
Franklin, Anna [1 ]
Zecca, Marco [1 ]
Fagioli, Franca [1 ]
Luisi, Flavio Augusto [1 ]
Song, Gregory [1 ]
Suri, Ajit [1 ]
Leonard, E. Jane [1 ]
Locatelli, Franco [1 ]
机构：
[1] Childrens Hosp Colorado, Aurora, CO USA
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
106
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Chen, Lu
    Herrera, Alex F.
    Mei, Matthew
    McBride, Katrina
    Abary, Rosie
    Siddiqi, Tanya
    Popplewell, Leslie
    Forman, Stephen J.
    Rosen, Steven T.
    Kwak, Larry W.
    BLOOD, 2018, 132
  • [22] Frontline Brentuximab Vedotin as Monotherapy or in Combination for Older Hodgkin Lymphoma Patients
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 9 - 10
  • [23] Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients
    Yasenchak, Christopher A.
    Bordoni, Rodolfo
    Patel-Donnelly, Dipti
    Larson, Timothy
    Goldschmidt, Jerome
    Boccia, Ralph V.
    Cline, Vivian J. M.
    Sacchi, Mariana
    Forero-Torres, Andres
    Sims, Robert B.
    Liu, Jingmin
    Friedberg, Jonathan W.
    BLOOD, 2020, 136
  • [24] Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Palmer, Joycelynne M.
    Herrera, Alex Francisco
    Armenian, Saro H.
    Mei, Matthew
    Popplewell, Leslie
    Fueger, Abbey
    Qasim, Imran
    Stiller, Tracy
    Rosen, Steven T.
    Forman, Stephen J.
    Kwak, Larry W.
    BLOOD, 2017, 130
  • [25] SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).
    Herrera, Alex Francisco
    LeBlanc, Michael Leo
    Castellino, Sharon M.
    Li, Hongli
    Rutherford, Sarah C.
    Evens, Andrew M.
    Davison, Kelly
    Punnett, Angela
    Hodgson, David C.
    Parsons, Susan K.
    Ahmed, Sairah
    Casulo, Carla
    Bartlett, Nancy L.
    Song, Joo Y.
    Little, Richard F.
    Kahl, Brad S.
    Leonard, John Paul
    Kelly, Kara M.
    Smith, Sonali M.
    Friedberg, Jonathan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [26] Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
    Steiner, Raphael E.
    Hwang, Steven R.
    Khurana, Arushi
    Habermann, Thomas M.
    Epperla, Narendranath
    Annunzio, Kaitlin
    Allen, Pamela Blair
    Baird, Katelin
    Paulino, Darina
    Alderuccio, Juan Pablo
    Lossos, Izidore S.
    David, Kevin
    Evens, Andrew M.
    Pandya, Karan
    Bair, Steven M.
    Kamdar, Manali
    Aqeel, Sheeba Ba
    Torka, Pallawi
    Lynch, Ryan
    Smith, Stephen
    Feng, Lei
    Noorani, Mansoor
    Ahmed, Sairah
    Nair, Ranjit
    Vega, Francisco
    Wu, Susan
    Fang, Penny
    Pinnix, Chelsea C.
    Gunther, Jillian R.
    Dabaja, Bouthaina S.
    Lee, Hun J.
    BLOOD ADVANCES, 2023, 7 (24) : 7485 - 7493
  • [27] Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma
    Mei, Matthew
    Tsai, Ni-Chun
    Palmer, Joycelynne
    Armenian, Saro
    Chen, Robert
    Rosen, Steven
    Forman, Stephen
    Popplewell, Leslie
    Kwak, Larry
    Martin, Peter
    Maddocks, Kami
    Bond, David
    Herrera, Alex F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (08): : 537 - 542
  • [28] Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
    Kambhampati, Swetha
    Mei, Matthew
    Chen, Lu
    Puverel, Sandrine
    Chen, Robert
    Popplewell, Leslie L.
    Nikolaenko, Liana
    Peters, Lacolle
    Armenian, Saro H.
    Kwak, Larry W.
    Rosen, Steve T.
    Forman, Stephen J.
    Herrera, Alex F.
    BLOOD, 2022, 140 : 9418 - 9419
  • [29] Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.
    Yasenchak, Christopher A.
    Bordoni, Rodolfo Eduardo
    Patel-Donnelly, Dipti
    Larson, Tim
    Goldschmidt, Jerome H.
    Boccia, Ralph, V
    Cline, Vivian Jean M.
    Forero-Torres, Andres
    Sims, Robert Brownell
    Newhook, Trevor
    Friedberg, Jonathan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
    Thiruvengadam, Swetha Kambhampati
    Mei, Matthew G.
    Chen, Lu
    Puverel, Sandrine
    Chen, Robert
    Popplewell, Leslie L.
    Nikolaenko, Liana
    Peters, Lacolle
    Armenian, Saro
    Kwak, Larry W.
    Rosen, Steven T.
    Forman, Stephen J.
    Herrera, Alex F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (10):
12345